IL2 and ovarian cancer: In this sense, Cheng et al. introduced an innovative “miniDC” nanovaccine, composed of PLGA NPs encapsulating IL-2 and coated with CMs from bone marrow–derived dendritic cells primed with ovarian cancer cell lysates (Fig. 9).